Venture capital firms are largely staying away from biotech, says Forbes' Bruce Booth. Reduced capital is a cyclical issue, and even with the problems in the biotech sector, bioentrepreneurs are still raising billions of dollars, he says. But what's really concerning is that the number of venture firms investing in biotech is shrinking and they're becoming less diverse.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.